We evaluated the effects of recombinant porcine somatotropin (pST) and the b-adrenergic agonist salbutamol on plasam endocrine and metabolite profiles and muscle chemistry in three genotypes of growing barrows ( n = 96, 139 d old). Treatments were in a 2 × 2 × 3 factorial arrangement, and main effects were pST ( 0 or 4 mg/d) and salbutamol ( 0 or 2.75 ppm); the three genotypes including purebred Meishan (M), 1/4 Duroc, 3/4 White composite ( D × Wc), and 1/4 Meishan, 3/4 White composite ( M × Wc). Individual pigs were injected daily with buffer or pST at 0700 and allowed ad libitum access to a corn-soybean meal diet (1.2% lysine) and water for 33 d. Plasma was obtained 4 h after injection and 3 h postprandially on d 0, 14, and 28 for determination of growth hormone (GH), insulin, IGF-I, glucose, urea N (PUN), NEFA, triglycerides, and cholesterol. Longissimus and semitendinosus samples were obtained, and protein, RNA, and DNA were quantified and loin chop shear force was measured. In general, plasma hormones and metabolites on d 14 and 28 were not affected by salbutamol in the absence of pST, although salbutamol tended to increase d 14 and 28 GH concentrations. Salbutamol lowered plasma IGF-I ( d 14 and 28, P < .05), insulin ( d 14, P < .01), and NEFA ( d 28, P = .07) when pST was administered, although concentrations still exceeded those for control pigs. Salbutamol reduced ( P < .05) IGF-I in M and M × Wc pigs, and GH was not changed in M pigs. Meishan pigs had a greater increase in glucose with pST than M × Wc or D × Wc pigs, although the effect was not consistent over time. Individual treatment with pST caused GH, insulin, IGF-I, glucose, NEFA, and triglycerides to be increased and PUN to be decreased on d 14 and 28. Cholesterol on d 14 and 28 was decreased by pST in M pigs, whereas no effects were found in the other genotypes. Muscle protein and RNA were increased by salbutamol and were consistently lowest for M pigs. Furthermore, pST did not affect muscle protein, but it increased RNA more in M pigs than in the others. Overall, pST and salbutamol seemed to act separately and by different mechanisms to alter muscle composition, but blood criteria generally representing fat metabolism (insulin, glucose, NEFA, triglycerides) were interactively affected. Meishan pigs tended to have greater changes in muscle and plasma composition with pST treatment than did M × Wc or D × Wc pigs.
Introduction
Exogenous administration of porcine somatotropin ( pST) alters carcass composition and visceral organ mass of growing swine (see Beermann, 1989; Boyd and Bauman, 1989; Brier and Gluckman, 1991) . Etherton et al. (1987) demonstrated linear increases in serum growth hormone ( GH) , insulin, and IGF-I with increasing pST dosage, whereas pST caused only minor changes in glucose and NEFA. Goodband et al. (1990) found that similar response criteria were affected by the plane of nutrition; they were increased by increasing dietary lysine in pST-treated pigs.
Salbutamol (hemisulfate salt; a-[(t-butylamino)methyl]4-hydroxy-m-xylene-a,a′-diol; molecular weight 288.4), a b-adrenergic agonist, has been evaluated to a limited extent in swine (Cole et al., 1988; Oksbjerg et al., 1990; Warris et al., 1990a,b) . Furthermore, metabolic indices among b-adrenergic agonists are variable after chronic treatment (Yen et al., 1990a,b; . Mersmann (1989a,b) contended that b-adrenergic agonists acutely increase NEFA release from adipocytes, thus accounting for the reductions in carcass lipid content. However, Yen et al. (1990a Yen et al. ( ,b, 1991 failed to demonstrate these responses after chronic exposure to similar compounds.
Combined use of somatotropin and a b-adrenergic agonist has given mixed results with regard to muscle protein, RNA, and DNA properties (Maltin et al., 1990; Bates and Pell, 1991) . Somatotropin increases muscle protein and RNA (Bates and Pell, 1991) , as do b-adrenergic agonists to various degrees (Beermann et al., 1987; Bergen et al., 1989) . However, the means by which these compounds increase protein accretion has not been fully described.
Therefore, the objectives of our research were to evaluate the combined use of pST and salbutamol on endocrine and blood chemistry indices and to characterize the effects on muscle protein, RNA, and DNA, and shear force criteria in swine differing in lean and lipid deposition potential.
Materials and Methods

Animals and Environment. Detailed information
about animals and environment were described in a companion article (Hansen et al., 1997) . Briefly, a 2 × 2 × 3 factorial arrangement with two intramuscular dosages of pST ( 0 or 4 mg/d) and two dietary levels of salbutamol ( 0 or 2.75 ppm) were administered to three different genotypes of pigs. The dosage of pST was within an effective dose range based on the findings of Etherton et al. (1987) , Evock et al. (1988) , and Krick et al. (1992) . The dosage of salbutamol was based on observations by Warriss et al. (1990a,b) . The following genotypes were evaluated: 1/4 Duroc, 3/4 MARC White Composite ( D × Wc) , 1/4 Meishan, 3/4 MARC White Composite ( M × Wc) , and purebred Meishan ( M) . The MARC White Composite was 1/4 Chester White, 1/4 Landrace, 1/4 Large White, and 1/4 Yorkshire. A 10-mL blood sample was obtained between 1100 and 1200 from the anterior vena cava with a heparinized syringe 4 h after pST injection and 3 h after feeder removal on d 0, 14, and 28. These sampling times were selected based on previous studies evaluating the effects of pST on blood variables (Etherton et al., 1987; Campbell et al., 1990; Caperna et al., 1990; Goodband et al., 1990) . Samples were placed on ice immediately after collection, and plasma was obtained by centrifugation within 30 min after sampling and stored at 4°C. Plasma metabolites were determined within 8 h after sampling, and the remaining plasma was stored at −20°C for hormone analyses. Pigs were slaughtered after approximately 34 d on test and skinned, and 50-g samples of longissimus and semitendinosus were removed within 30 min of death. Exterior portions of each muscle sample were trimmed, and the interior portion was rapidly frozen in liquid nitrogen ( −210°C) for subsequent determinations of protein, RNA, and DNA. Loin chop samples for shear analyses were removed at 6 h postmortem.
In addition, eight pigs from each genotype were slaughtered at the beginning of the study (initial slaughter group). Samples from longissimus and semitendinosus muscles were obtained and characterized as described for the test group of pigs, as well as loin chops for shear force evaluation.
Radioimmunoassays. Plasma concentrations of growth hormone were determined using a heterologous double antibody RIA with USDA pGH B1 as the reference preparation (Klindt et al., 1983) . The sensitivity was 58 pg/mL, and the intraassay and interassay CV averaged 9.5 and 13.9%, respectively. Insulin concentrations were determined in a single assay using a kit (Coat-A-Count Insulin, Diagnostic Products, Los Angeles, CA). The sensitivity and intraassay CV were .96 mIU/mL and 5.42%, respectively. Plasma concentrations of IGF-I were determined after acid-ethanol extraction in a heterologous double antibody RIA (Trout and Schanbacher, 1990) . Assay sensitivity was 21.9 ng/mL, and the intraassay CV was 13.6%.
Plasma Metabolites. The following plasma metabolites were quantified using kits from Ciba-Corning Diagnostics Corp. (Gilford Systems, Oberlin, OH): glucose using hexokinase and glucose-6-phosphate dehydrogenase (Gilford Glucose HK Reagent); plasma urea N ( PUN) using urease and glutamate dehydrogenase (Gilford BUN Reagent); and cholesterol using cholesterol esterase, cholesterol oxidase, and hydrogen peroxide (Gilford Cholesterol Reagent). Triglyceride concentration was determined using an enzymatic colorimetric procedure employing lipase, glycerol kinase, glycerol phosphate oxidase, and peroxidase (Amresco Triglycerides [GPO] Reagent, AM-RESCO Inc., Solon, OH). Also, nonesterified fatty acids were determined colorimetrically with an enzymatic procedure using acyl CoA synthetase, acyl CoA oxidase, and peroxidase (Wako NEFA C, Wako Pure Chemical Industries, Okasaka, Japan).
Carcass Muscle Characteristics. Four 2.54-cm boneless loin chops were removed from the 11th thoracic vertebrae continuing no more than 15 cm posterior, vacuum packaged, stored at 2°C, and then frozen ( −15°C ) at 96 h postmortem. Thaw losses were computed by subtracting the thawed weight from the frozen weight, and cooking loss was obtained by subtracting the cooked weight from the thawed weight. Chops were cooked to an internal endpoint temperature of 75°C and analyzed for shear force using an Instron (Instron Corp., Canton, MA) equipped with a Warner-Bratzler attachment. Specific procedures are described in more detail elsewhere (Yen et al., 1991) .
Protein and Nucleic Acids. Muscle samples were removed from storage and kept in liquid nitrogen, then crushed into small pieces and pulverized while frozen using a blender. Samples were kept on dry ice until 1 g was weighed into a 50-mL centrifuge tube containing 22 mL of cold ( 5°C ) KCl (.4 N with 2 mM EDTA) buffer and subsequently homogenized using three 10-s bursts from a variable speed homogenizer (Polytron PT 10/35, Brinkman Instruments, Westbury, NY) at setting 7. The homogenizer shaft was then rinsed with 3 mL of cold KCl to obtain a final volume of 25 mL. Samples were allowed to stand overnight at 5°C and mixed the next morning to disperse the accumulated foam; then 5 mL of cold perchloric acid (1.2 N) was added. The samples were refrigerated ( 5°C ) for 30 min and then centrifuged at 10,000 × g for 5 min at 8°C. Supernatant was discarded, 10 mL of cold perchloric acid (.2 N) was added, the pellet was broken up with a glass rod, and then the mixture was centrifuged at 10,000 × g. This was repeated twice for a total of three rinses with cold .2 N perchloric acid. After the last rinse, 20 mL of .3 N KOH buffer was added, and the pellet was broken up with a glass rod, homogenized with a Polytron at setting 7 for 7 s, and then placed in a water bath (37°C ) for 1 h. Tubes were mixed at 12-min intervals throughout digestion. After digestion, the samples were allowed to cool for 5 min and then subsampled for RNA and protein analyses.
The procedure used to measure protein was a modification of that described by Lowry et al. (1951) . Briefly, .5 mL of digested sample was diluted to 20 mL with .3 M NaOH in 50-mL tubes and mixed. Subsequently, .1 mL was mixed in duplicate with .4 mL of distilled-deionized water in borosilicate glass tubes; then 2.5 mL of a solution containing .2647 mg of Na K tartrate pentahydrate, .1529 mg of CuSO 4 ·5H 2 O, 19.61 mg of sodium carbonate (anhydrous), and 3.92 mg of NaOH per milliliter was added, mixed, and allowed to incubate for 10 min at room temperature in the light. Then, .25 mL of a solution containing 50% Folin & Ciocalteu's phenol ( 2 N; Sigma Chemical, St. Louis, MO; 50:50, vol/vol, with distilled-deionized water) reagent was added, and the mixture was allowed to incubate for 30 min in the dark at room temperature. Absorbance was measured with a spectrophotometer at 750 nm using a bovine serum albumin standard with a reagent blank (distilled water rather than BSA). A common BSA control was included daily for calculation of interassay CV (4.2%).
The procedure for quantifying RNA was similar to that described by Munro and Fleck (1969) . Digested sample ( 3 mL) was pipetted into duplicate plasticcapped tubes, the tubes were placed on ice for 10 min, and then 2 mL of cold 1.2 N perchloric acid was added and mixed. Tubes were centrifuged (10,000 × g) for 5 min, and the supernatant was collected into 15-mL vials. Then, 1 mL of cold .2 N perchloric acid was added to each tube, pellets were broken up with a glass rod, mixed, and centrifuged, and the supernatant was collected as described above. A total of two rinses was used to yield approximately 7 mL of supernatant. The supernatants were mixed, and absorbance was measured with a spectrophotometer at 232 and 260 nm. A reagent blank using distilled water instead of sample was used to zero the spectrophotometer. Also, a daily control (Type XII Fetal Calf Thymus RNA, Sigma R-4007; Sigma Chemical) was included for determination of interassay CV (3.7%). Muscle RNA content was estimated with the following equation: mg RNA/g tissue = ([39.1 × absorbance 260] − [15.5 × absorbance 232]) × dilution factor/sample weight. The dilution factor was calculated as follows: mL of supernatant ÷ (sample volume × volume of initial homogenate).
For DNA, the procedure used was based on that described by LaBarca and Paigen (1980) . Pulverized muscle samples were kept on dry ice until ∼1 g was weighed into a 50-mL centrifuge tube containing 27 mL of cold ( 5°C ) .05 M PBS with 2.0 M NaCl and 2 × 10 −3 M EDTA (pH 7.4) and homogenized using three 10-s bursts from a variable speed homogenizer (Polytron PT 10/35, Brinkman Instruments) at setting 7. The homogenizer shaft was then rinsed with 3 mL of cold PBS to obtain a final volume of 30 mL, which was mixed and held on ice. Duplicate 1-mL homogenized samples were diluted to a final volume of 10 mL with room temperature PBS. Then .75 mL of each diluted sample was mixed in duplicate with .75 mL of PBS and .75 mL of a 1 mg/mL Hoechst 33258 dye (Sigma Chemical) solution and incubated at room temperature in the dark for 30 min. Sample concentrations were routinely quantified fluorometrically using an Aminco Fluorocolorimeter (model J4-7439) with a Corning 7-60 primary excitation filter and a Wratten 2A emission cut-off filter. Calf thymus DNA (Sigma D 3664, Sigma Chemical) was used as a standard. Single-stranded calf heart DNA (Sigma D 8899, Sigma Chemical) was used as a daily control for determination of interassay CV (11.7%).
Statistical Analyses. Pigs were penned individually and considered the experimental unit. Analyses of variance was conducted using the GLM procedure of SAS (1988) as a completely randomized design. Class variables for blood data included in the model were pST, salbutamol, and genotype, and all two-and three-way interaction terms appropriate for a 2 × 2 × 3 factorial treatment arrangement where appropriate muscle type was also included according to a 2 × 2 × 2 × 3 factorial. Repeated measures analysis of variance was used for blood measurements with the GLM procedure of SAS (1988) . For plasma criteria, relationships were first evaluated with time in the model, and without time at individual time points if interactions with time were not found or to explain time × treatment interactions. Class variables for carcass muscle characteristics typically included pST, salbutamol, genotype, muscle, and all two-, three-, and four-way interaction terms appropriate for a 2 × 2 × 2 × 3 factorial treatment arrangement. However, a reduced model without muscle was used for analysis of criteria for total contents of semitendinosus muscle. For individual time points and for muscle criteria, a protected least significant difference test was used to separate means once a significant F-ratio was observed for genotype or interaction effects. Because of missing observations, all values reported herein are least squares means, and variance is reported as the pooled SD.
Results
Blood Hormones and Metabolites
Individual treatment means for blood criteria are presented in Table 1 . Because data were analyzed using repeated measures analysis of variance, the probability values and error terms associated with Fstatistics for the analyses of between-pig effects (independent of time) and within-pig effects (across time) are presented in Table 2 .
Growth Hormone. Overall, a time × pST interaction ( P < .001) was observed because pST increased plasma GH levels on d 14 (+11.4 ng/mL) and d 28 (+13.4 ng/mL); the increase caused by pST was quadratic over time. Similarly, a time × salbutamol interaction ( P < .02) was observed, which was due to a change in GH concentrations between salbutamol treatments on d 14 and 28, and there tended ( P = .11) to be a time × salbutamol × genotype interaction. These interactions were due to no difference between salbutamol treatments on d 14 ( P > .20), but a genotype × salbutamol interaction on d 28 ( P = .07). Meishan pigs did not have a change in GH from salbutamol, whereas D × Wc pigs had increased concentrations (+4.3 ng/mL), and M × Wc pigs only tended (+2.7 ng/mL) to have increased GH levels. Plasma GH was similar among genotypes at all times independent of pST and salbutamol treatments.
Insulin.
A time × pST × salbutamol interaction ( P < .06) was observed for plasma insulin. Although pST consistently increased ( P < .001) insulin (+34 mIU/ mL) on d 14 and 28 when pigs received no salbutamol, the addition of salbutamol to the diet caused significant ( P < .01) reductions in plasma insulin ( −19 mIU/ mL) on d 14 only when pigs received pST. This effect was not observed on d 28 ( −8 mIU/mL), although the effect from pST was maintained. Furthermore, when pigs received buffer, no effect was observed from salbutamol at either time point. Genotype had no significant effect on plasma insulin concentrations, although there tended ( P = .12) to be an interaction between pST and genotype on d 14 because M × Wc pigs had a greater increase in plasma insulin (+32.9 mIU/mL) when injected with pST than did D × Wc pigs (+19.3 mIU/mL) or M pigs (21.8 mIU/mL).
Insulin-like Growth Factor-I. Overall, time × genotype ( P < .02) and time × pST ( P < .001) interactions occurred for IGF-I concentrations. No differences occurred among genotypes on d 0, but on d 14 and 28, the genotype and pST affected IGF-I interactively with salbutamol ( P < .05). The genotype × salbutamol interaction was accounted for by salbutamol causing a decrease in plasma IGF-I in M pigs ( −274 ng/mL) but not in D × Wc pigs (+52 ng/mL) or M × Wc pigs ( −138 ng/mL) on d 14 and 28. Also, for pigs receiving no salbutamol, d 14 IGF-I was greater for M × Wc pigs than for D × Wc or M pigs, but this was not found on d 0 or 28, which accounts for the interaction between time and genotype. The interaction between pST and salbutamol followed a pattern similar to that for insulin. When pigs received no salbutamol and were injected with pST, the average increases in IGF-I on d 14 and 28 were 760 and 930 ng/mL, respectively, but when pigs received both pST and salbutamol, the average increases were reduced to +531 and 670 ng/ mL on d 14 and 28, respectively. Also, in the absence of pST administration, salbutamol elicited no effect. The average change in IGF-I from pST increased from d 14 to 28, whereas the average without pST did not seem to change, which accounts for the interaction between time and pST dosage.
Glucose. Plasma glucose was interactively influenced by pST over time ( P < .001). The interaction is characterized by pST increasing glucose on d 14 and 28 ( P < .001), but there was no change between the increase from d 0 to d 14 or 28 with pST, which accounts for the interaction. On d 14, pST tended ( P < .09) to increase glucose more in M pigs (+46 mg/dL) than in D × Wc (+26 mg/dL) or M × Wc (+22 mg/dL) pigs; however, this relationship was not apparent on d 28 ( P > .19). Salbutamol treatment did not affect plasma glucose on d 14 or 28.
Plasma Urea Nitrogen. There was a tendency ( P = .10) for a time × genotype × pST × salbutamol interaction. Because this interaction was not significant at d 14 or 28 ( P > .46), we believe it to be more closely related to initial values before pST or salbutamol treatment. Partial correlation analysis of the residual matrices indicated that d 14 and 28 PUN levels were highly correlated with d 0 levels ( r = .45 and .54, respectively, P < .001), and d 14 levels were correlated to d 28 levels ( r = .66, P < .001). Thus, this interaction may not be related to treatment differences. A time × pST interaction ( P < .001) was observed because pST consistently decreased PUN by −10 mg/dL on d 14 and 28 ( P < .001), and the relative change between d 0 and 14 was greater than that between d 14 and 28, resulting in a significant interaction term. Differences between genotypes were also observed on d 0 and 14 ( P < .01), but they became less apparent on d 28 ( P = .09). These differences were characterized by M × Wc pigs having the highest PUN at all three times, but these levels were not different from those of D × Wc pigs at d 14 and only tended to be different on d 28 ( P < .09). However, M pigs consistently had lower PUN than M × Wc pigs, but no difference was observed between M and D × Wc pigs. Salbutamol did not affect PUN when considering individual time point analyses.
Nonesterified Fatty Acids. Daily injection of pST increased NEFA on d 14 and 28 by a similar magnitude, resulting in the time × pST interaction ( P < .001). However, pST did not act independently of salbutamol treatment when time was removed from the overall model ( P = .05), which was most evident on d 28 ( P = .07). The interaction between pST and salbutamol was due to salbutamol decreasing NEFA when pigs were injected with pST but causing no change when pigs received buffer. When pigs were injected with pST, salbutamol caused NEFA to be reduced by 116 and 114 mmol/mL on d 14 and 28, but because of the greater error variance on d 14 than on d 28 (SD = 175 and 146, respectively), the F-ratios and their corresponding probability values were different ( P = .11 and P = .07, respectively). Nevertheless, we believe these changes are repeatable based on the similar responses between d 14 and 28, which is supported by the overall model. Cholesterol. The interaction for time × genotype × pST × salbutamol was significant ( P < .03), but as with PUN, the interaction seemed to be more related to initial cholesterol measurements than to treatments. Residual partial correlation coefficients were high between d 0 and d 14 and 28 ( r = .58 and .57, respectively, P < .001) and between d 14 and 28 ( r = .71, P < .001). Thus, more of the variance may be accounted for by individual animals than by our model. Therefore, results for treatment effects will be considered independently of time. Overall, pST did ) and between muscle types (T). † P < .10, *P < .05, **P < .01, ***P < .001.
Triglycerides. Time
c See 
Carcass Muscle Characteristics
Initial Slaughter Group. Data for the initial slaughter group are presented in Table 3 . No differences were observed among genotypes for longissimus thaw loss, cooking loss, or shear force. Regardless of genotype, longissimus muscles had more protein than did semitendinosus muscles ( P < .001), and within each muscle, differences among genotypes were not evident. Ribonucleic acid content was not different between the muscle groups, but was greatest for D × Wc pigs averaged across muscles, whereas the purebred and crossbred M genotypes did not differ. Deoxyribonucleic acid was lower in longissimus muscles, and no differences were observed for DNA among genotypes. The total quantities of protein, RNA, and DNA in the semitendinosus muscle were different among all three genotypes, which is best reflected by the total weight of semitendinosus for each genotype (i.e., D × Wc > M × Wc > M; see Hansen et al., 1997) . The ratio of RNA:DNA was greater in D × Wc pigs than M or M × Wc pigs for both muscles ( P < .01). The protein:RNA ratio was greater in longissimus, but across muscles, M and M × Wc pigs had greater ratios than did D × Wc pigs. Similarly, longissimus muscle had a greater protein:DNA ratio ( P < .001) than did semitendinosus.
Test Group. Mean values for carcass muscle charac-
teristics of the test group of pigs are presented in Table 4 . Thaw loss was not different among treatment groups, but chops from pigs injected with pST had greater cooking loss than those from pigs receiving buffer (+1.76 percentage units or 5% greater loss; P < .05). Also, pST increased shear force values across genotypes ( P < .01), and chops from M pigs required more energy for shear (+1.5 kg/cm 3 on average) than did chops from D × Wc or M × Wc. Relative quantities of protein, RNA, and DNA were different between muscles ( P < .001), with longissimus muscle being higher in protein and DNA, whereas semitendinosus muscles contained more RNA. Across muscles, salbutamol caused protein content to be increased by +6 mg/g ( P < .001), and M pigs had less protein (approximately −6 mg/g) than either D × Wc or M × Wc pigs ( P < .01). Somatotropin did not affect the amount of protein per unit mass in either muscle. Ribonucleic acid content was independently increased by salbutamol (+18 mg/g, P < .05), but it was interactively affected by genotype and pST ( P < .001).
The interaction resulted in M pigs having the greatest increase in RNA (+147 mg/g); M × Wc pigs were intermediate (+127 mg/g), and D × Wc had the least degree of change (+78 mg/g). However, regardless of genotype, the increase was significant ( P < .001). For DNA, a genotype × pST × salbutamol interaction was characterized by M pigs having an increase in DNA (T). † P < .10, *P < .05, **P < .01, ***P < .001.
c See Table 7 of Hansen et al. (1997) for actual weights. when they received pST and salbutamol; salbutamol treatment alone resulted in the lowest muscle DNA. Thus, the greatest difference was observed between salbutamol and the combined use of pST and salbutamol. For the crossbred pigs, pST tended to increase DNA, but no clear patterns were observed. Differences were noticed between muscles when the RNA:DNA ratio was evaluated, with ratios being consistently higher in semitendinosus than longissimus ( P < .001). Also, the ratio was interactively affected by genotype and pST ( P < .05), resulting from M and M × Wc pigs having greater increases in RNA: DNA than D × Wc pigs, and M and D × Wc pigs having similar ratios without pST, which were greater ratios than for M × Wc pigs. Meishan pigs had the highest ratio, and M × Wc and D × Wc pigs had similar ratios. Conversely, the protein:RNA ratio decreased with pST administration, but the degree of decrease was greater for M and M × Wc pigs than for D × Wc pigs, although M × Wc pigs had the highest ratio without pST. Thus, comparing genotypes when pST was administered, M pigs had the lowest ratio, whereas no difference was observed between M × Wc and D × Wc pigs. Also, the degree of decrease from pST was greater in longissimus muscle than in semitendinosus. No interactions were observed for the protein:DNA ratio, and it was decreased by pST ( −8 g/mg) and tended ( P = .06) to be increased by salbutamol (+6 g/mg). Total contents of protein in the semitendinosus were interactively increased by salbutamol with genotype. This resulted because M pigs (+.8 mg) were not affected by salbutamol, whereas D × Wc pigs (+13 mg) and M × Wc (+8 mg) pigs had increases in total protein. Somatotropin injection resulted in an average increase of 8 mg of protein regardless of genotype or salbutamol treatment. Total RNA followed a similar pattern to protein; M × Wc and D × Wc pigs had increases in total RNA (+22 and 36 mg, respectively), whereas M pigs did not (+3 mg). Total DNA was increased by 32 and 24 mg in D × Wc and M × Wc pigs when salbutamol was included in the diet, but M pigs were not affected (+1.5 mg). However, total DNA was increased across genotypes by pST (+28 mg). As with the initial slaughter group, total RNA, DNA, and protein were greatest for D × Wc, intermediate for M × Wc, and lowest for M pigs.
Discussion
Increased plasma GH concentrations observed in this experiment with pST administration are consistent with previous research that demonstrated a dosedependent relationship for plasma GH levels (Etherton et al., 1987; Evock et al., 1988) . Limited research has indicated that b-adrenergic agonists can stimulate GH secretion from the rodent anterior pituitary cells in vitro (Perkins et al., 1983 (Perkins et al., , 1985 . Beermann et al. (1987) found that serum GH levels of sheep fed cimaterol were increased after 6 wk on trial, but the differences diminished by wk 12 of the experiment. In the present study, salbutamol produced an increase of plasma GH on d 28 but not on d 14. In rodents, prolonged exposure to cimaterol causes skeletal tissues to become refractory, an effect associated with reduced receptor density (Kim et al., 1992) . The increase in plasma GH on d 28 would seem contradictory to this response, yet it may not be the same in the hypothalamus and pituitary as in skeletal muscles. The relatively short duration of the present study may still be within the most effective time range for salbutamol. It is difficult to ascertain whether the increase in GH concentrations caused by salbutamol would be observed consistently with other b-adrenergic agonists. No effect of clenbuterol on plasma GH level was observed in lambs by Claeys et al. (1989) .
Increases in circulating insulin and glucose have been observed consistently when pigs are injected with pST (Gopinath and Etherton, 1989a,b; Dunshea et al., 1992a) . Gopinath and Etherton (1989b) suggested that increased hepatic glucose output and reduced clearance rates or a reduced adipocyte sensitivity to insulin is responsible for increased plasma glucose concentrations. In the present experiment, circulating glucose was increased by pST more in M pigs on d 14 than in the other two genotypes, and plasma insulin tended to be increased more in M × Wc pigs than in either M or D × Wc pigs. Dunshea et al. (1992b Dunshea et al. ( , 1996 suggested that pST-induced hyperglycemia was most likely due to a reduced utilization by peripheral tissues. Also, Klindt et al. (1992) found that glucose was increased more by pST in pigs selected for obesity. As for insulin, the trend for interaction remains unclear, mainly because M pigs had greater pancreas weights than the other two genotypes initially (Hansen et al., 1997) , which would be reflective of the higher insulin concentrations on d 0. However, changes in endocrine and metabolite profiles are not entirely dependent upon organ size.
The tendency for salbutamol to reduce insulin may have been related to changes in organ size (Hansen et al., 1997) , but a more likely explanation may be that the b-receptors for salbutamol on cells affect hormonal interaction with these cells. This seems probable because insulin and NEFA were reduced simultaneously when pigs were injected with pST and received salbutamol. These relationships, along with the relatively small change in carcass fat from salbutamol (Hansen et al., 1997) , indicate that fat storage and breakdown are not substantially affected by salbutamol. This is contrary to the results of Mersmann (1989a,b) , who found that acute administration of badrenergic agonists stimulated NEFA release from adipocytes. Webster et al. (1986) suggested that insulin binding to skeletal muscle may be induced via b-adrenergic receptors. Thus, one possible explanation for the simultaneous reduction in plasma insulin and NEFA is that muscle cells, rather than adipocytes, utilized NEFA because insulin effectively bound to these cells. Another possibility is that salbutamol indirectly alters the transmembrane signal of insulin for a reduction in intracellular triglyceride breakdown, but this seems unlikely because of the decrease in carcass lipid content (Hansen et al., 1997) across pST treatments. Finally, because plasma samples were taken consistently 4 to 5 h after pST injection and 3 to 4 h postprandial, it is possible that concentrations of hormones and metabolites may not actually reflect the true metabolic state, but rather a feed-deprived state. This is also true for salbutamol, because it may have been metabolized by the time blood samples were taken after feeders were removed.
Cholesterol demonstrated the lowest amount of variation with respect to the overall model; however, treatment effects are not easily interpreted. Although evidence suggested that pST would increase plasma cholesterol (Oscarsson et al., 1989) , we believe one explanation may be found by examining the correlation coefficients for the residual matrices. Once expected treatment effects were removed, the correlations for the three times remained high ( r > .57, P < .001). This would suggest that the mean values for d 14 and 28 strongly reflect the initial cholesterol levels. Considering the variability in the mean concentrations on d 0, it is apparent that d 14 and 28 levels may be biased by treatment assignment. Nevertheless, genotype differences did seem to exist, but they were interactively affected by pST. These interactions may have been related to differences in total body fat and(or) organ weights, but no clear patterns were observed throughout this study. Harris et al. (1993) suggested that breed differences exist for liver cholesterol but not for muscle tissues. The effects of these compounds should be evaluated in additional controlled studies.
Muscle protein accretion is known to be affected directly via somatotropin receptors and indirectly through IGF-I (see reviews by Pell and Bates, 1990; Brier and Gluckman, 1991) . We observed increases in circulating IGF-I and GH when pigs were injected with pST, and increases in either IGF-I or GH could have been responsible for increased protein deposition (Hansen et al., 1997) . The differential response in IGF-I to salbutamol among genotypes presents difficulty in interpreting the results, and we cannot offer a reasonable explanation for it when considering the other effects. In M and M × Wc pigs, salbutamol decreased plasma IGF-I only when pigs were injected with pST; thus, circulating IGF-I may not have been entirely responsible for the changes observed in protein accretion. This is best represented by the additive increase in protein deposition (Hansen et al., 1997) and total protein of the semitendinosus. Furthermore, the responses of IGF-I, insulin, and NEFA elicited by salbutamol present interesting questions regarding the mechanisms by which salbutamol and pST mediate their effects on muscle and adipose cells. Because these effects did not occur at the same times, the responses may be through different mechanisms.
Salbutamol did not affect PUN, and this result is consistent with reports of ractopamine use in swine (Yen et al., 1990a) . However, Yen et al. (1990b) also observed an increase in urea N in feed-deprived pigs when similar genotypes were treated with cimaterol. The reason for the discrepancy between these two reports is unclear, but one possibility may be related to the fact that the two b-adrenergic agonists are known to bind to receptors with differing specificities. Somatotropin reduced PUN, which suggests that it causes an increase in the efficiency of amino acid retention by the animal. This is most evident when the total amount of protein retained in each pig carcass is considered. Even though differences were not apparent for increased muscle protein, increases occurred in total protein for the semitendinosus and also total carcass protein (Hansen et al., 1997) . These observations suggest hypertrophy of the muscular tissues, as was evident by the proportional increases in carcass water with pST treatment. Furthermore, pST increased the concentrations of RNA, thus lowering the protein:RNA ratio, which suggests less protein synthesized per unit of RNA. One possibility is that protein synthesis is being limited by at least one amino acid; however, the diet fed seemed to be an adequate nutrient source (Hansen et al., 1994) in similar weight pigs. Maltin et al. (1990) , using calves, found that the combined use of bovine GH and clenbuterol did not alter protein content of semimembranosus or triceps muscles, whereas Bates and Pell (1991) found that GH and clenbuterol caused an additive increase in protein content of skeletal muscle in dwarf mice. Maltin et al. (1990) also reported that GH increased DNA only when used alone, but they did not observe differences in RNA contents. Bates and Pell (1991) observed results similar to those of the present experiment for reductions in the amount of protein per unit RNA with pST, but they also observed a reduction with clenbuterol, whereas we observed no effect. These discrepancies are thought to be due to the difference in pharmacological properties of different badrenergic agonists in different species. For example, Bergen et al. (1989) found that ractopamine did not affect semitendinosus protein, RNA, or DNA within the same time frame of the present experiment. Thus, we cannot draw broad-based conclusions from the present data with respect to efficacy and predicted response.
Salbutamol causes shifts in muscle protein that are proportional to increases in muscle RNA content. Because the protein:RNA ratio was unchanged and the protein:DNA ratio was greater with salbutamol treatment, we contend that salbutamol acts to increase muscle protein by increasing synthesis rates.
Alternatively, pST seems to affect protein degradation more than the rate of protein synthesis, because total muscle protein was increased but the relative concentrations were not. Furthermore, pST decreased the protein:RNA and protein:DNA ratios, indicating that nucleic acids were increased but the net output of protein was not. These responses followed the same pattern among genotypes, although the relative degree was greatest in the slower-growing M pigs. The additive increases in carcass protein are expected to be consistent, because the two growth modifiers clearly use different means to achieve the same end.
Shear force was increased in loin chops from pigs injected with pST, although the relative force is not beyond an acceptable range observed in a random sample of pork loins (De Vol et al., 1988) . This is consistent with data reported by Solomon et al. (1988 Solomon et al. ( , 1991 and Knight et al. (1991) but contradicts data reported by Prusa et al. (1989) . The most logical reason for expecting differences in shear force value is that pST increases muscle fiber size (Solomon et al., 1988; Lefaucheur et al., 1992) . One reason for the discrepancy in reported research may be related to the nutritional plane that pigs were maintained on during the growth phase. Goodband et al. (1990) found that shear force differed between muscles and between lysine levels for pST-treated pigs. Furthermore, they observed a linear increase in shear force values as lysine increased when pigs received pST, which further increased the difference between pST-treated animals and untreated controls. Analysis of muscle fiber data from that experiment (Whipple et al., 1992) suggested that muscle fiber areas were not directly related to increasing lysine level, although the authors observed a tendency. Overall, salbutamol did not affect shear force values, which is consistent with other reports for swine (Yen et al., 1991) but contradictory to reports considering other b-adrenergic agonists (Walker et al., 1989; Warriss et al., 1990a,b; Yen et al., 1990b) . The response to any one badrenergic agonist is not indicative of efficacy across species or genotypes.
Implications
The combined use of salbutamol and somatotropin additively increased muscle protein deposition. The means by which salbutamol and porcine somatotropin elicit their responses on carcass criteria are clearly different and are not masked by one another. We believe that salbutamol directly affects protein synthesis and suggest that somatotropin mediates its effects through some other means, such as reducing protein breakdown. The degree of response to porcine somatotropin and salbutamol depends on the genotype of interest, but neither compound completely alleviates differences between extremely diverse genotypes.
